Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bellus Health Inc (NQ: BLU )

8.210 -0.020 (-0.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 508,062
Open 8.220
Bid (Size) 7.860 (1)
Ask (Size) 8.550 (1)
Prev. Close 8.230
Today's Range 7.995 - 8.260
52wk Range 5.450 - 12.69
Shares Outstanding 55,378,660
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
From BELLUS Health Inc.
Via Business Wire

Performance

YTD
-3.64%
-3.64%
1 Month
+8.60%
+8.60%
3 Month
-7.96%
-7.96%
6 Month
-29.16%
-29.16%
1 Year
+20.38%
+20.38%

More News

Read More
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Shares Slide On Public Offering Of Shares In Canada And US
Via Benzinga
BELLUS Health Announces FDA End-of-Phase 2 Meeting For Refractory Chronic Cough Program
Via Benzinga
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
From BELLUS Health Inc.
Via Business Wire
Expert Ratings for BELLUS Health
Via Benzinga
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
From BELLUS Health Inc.
Via Business Wire
Here's Why BELLUS Health Shares Are Diving Lower Today
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Via Benzinga
U.S. Stock Futures Down Ahead Of Bank Earnings, Producer Price Index
Via Benzinga
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
From BELLUS Health Inc.
Via Business Wire
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Participate in the William Blair Biotech Focus Conference
From BELLUS Health Inc.
Via Business Wire
The Week In Charts: How To Make Money While Waiting For Core Trend Trades
Via Talk Markets
4 Biotech Stocks With Bright Prospects To Buy Amid Recovery
Via Talk Markets
BELLUS Health to Participate in the Jefferies Healthcare Conference
From BELLUS Health Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Via Benzinga
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
From BELLUS Health Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.